New diabetes drug XW003 shows promise in phase 3 trial
NCT ID NCT05680155
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This study tested a new medication called XW003 in 211 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either XW003 or a placebo to see if the drug could safely lower blood sugar levels (measured by HbA1c). The trial has been completed, and results will show how effective XW003 is compared to no additional treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
Conditions
Explore the condition pages connected to this study.